Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 11,277

Document Document Title
WO/2010/005560A3
Phytoplankton represent a potential source of bioactive compounds. The present disclosure provides, inter alia, methods for identifying glycerolipids and apoptosis- inducing sphingosine-like lipids from virally-infected phytoplankton.  
WO/2010/004433A3
Hydrophobically enhanced aminoglycosides have been prepared and shown to be effective antibacterial agents. These agents may be used in the treatment or prevention of various bacterial infections. Methods of preparing these agents also p...  
WO/2009/156324A3
Described is the use of benzotropolone and their derivatives, especially the compounds of formula (1); wherein R2, R3, R4, R5 and R6 independently of one another are hydrogen; OH; C1-C30alkyl, C2-C30al- kenyl, C1-C30alkoxy, C3-C12cycloal...  
WO/2009/156324A2
Described is the use of benzotropolone and their derivatives, especially the compounds of formula (1); wherein R2, R3, R4, R5 and R6 independently of one another are hydrogen; OH; C1-C30alkyl, C2-C30al- kenyl, C1-C30alkoxy, C3-C12cycloal...  
WO/2009/153434A8
The present invention relates to novel synthetic analogues of phosphatidyl-myo-inositol mannosides (hereinafter referred to as PIMs) of general formula (I): or a pharmaceutically acceptable salt thereof, to the method for preparing same ...  
WO/2009/153434A3
The present invention relates to novel synthetic analogues of phosphatidyl-myo-inositol mannosides (hereinafter referred to as PIMs) of general formula (I): or a pharmaceutically acceptable salt thereof, to the method for preparing same ...  
WO/2009/153509A2
Composition (C) comprising, per 100% of its weight: - from 10 wt% to 95 wt%, more particularly from 70 wt% to 95 wt% of one or more alcohol ethers of glycerol of formula (II): in which R1 represents a linear or branched, saturated or uns...  
WO/2009/153509A3
Composition (C) comprising, per 100% of its weight: - from 10 wt% to 95 wt%, more particularly from 70 wt% to 95 wt% of one or more alcohol ethers of glycerol of formula (II): in which R1 represents a linear or branched, saturated or uns...  
WO/2009/153434A2
The present invention relates to novel synthetic analogues of phosphatidyl-myo-inositol mannosides (hereinafter referred to as PIMs) of general formula (I): or a pharmaceutically acceptable salt thereof, to the method for preparing same ...  
WO/2009/150022A2
The invention relates to the enzymatic synthesis of sphingolipids and compositions that contain sphingolipids from lysosphingolipids and carbonic esters, and to cosmetic, dermatological or pharmaceutical formulations containing said sphi...  
WO/2009/150023A2
The invention relates to the enzymatic synthesis of sphingolipids and compositions that contain sphingolipids from lysosphingolipids and carbonic esters, and to cosmetic, dermatological or pharmaceutical formulations containing said sphi...  
WO/2009/150023A3
The invention relates to the enzymatic synthesis of sphingolipids and compositions that contain sphingolipids from lysosphingolipids and carbonic esters, and to cosmetic, dermatological or pharmaceutical formulations containing said sphi...  
WO/2009/150022A3
The invention relates to the enzymatic synthesis of sphingolipids and compositions that contain sphingolipids from lysosphingolipids and carbonic esters, and to cosmetic, dermatological or pharmaceutical formulations containing said sphi...  
WO/2009/143630A1
Compounds produced by combining imino sugars and creatine and salts thereof are herein disclosed. The compounds being in the form of creatine imino sugar amides and the salts being combinations of various creatine imino sugar amides with...  
WO/2009/143930A1
A process for the preparation of compounds having formula (I) is disclosed, wherein: - R1 is a methoxy or methylthio group; - R2 is a O-glycosyloxy residue. Compounds having formula (I) are prepared by reacting the corresponding precurso...  
WO/2009/139719A9
The present invention relates to novel synthesis routes for preparation of thiodigalactosides of the general formula (12). The method comprises the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corres...  
WO/2009/139719A1
The present invention relates to novel synthesis routes for preparation of thiodigalactosides of the general formula (12). The method comprises the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corres...  
WO/2009/135673A8
Compounds of the general formula (I) and (II) (including formulae (III) to (V)), wherein X - -CH2-, -O-, -S- n = 0-10 Y = -NH-, -NHSO2-, -NHSO-, -NHCO-, -S-, -O-, -CH=CH- R1-R7, equal or different can be hydrogen, alkyl C1-C4, alkenyl C2...  
WO/2009/135673A3
Compounds of the general formula (I) and (II) (including formulae (III) to (V)), wherein X - -CH2-, -O-, -S- n = 0-10 Y = -NH-, -NHSO2-, -NHSO-, -NHCO-, -S-, -O-, -CH=CH- R1-R7, equal or different can be hydrogen, alkyl C1-C4, alkenyl C2...  
WO/2009/135673A2
Compounds of the general formula (I) and (II) (including formulae (III) to (V)), wherein X - -CH2-, -O-, -S- n = 0-10 Y = -NH-, -NHSO2-, -NHSO-, -NHCO-, -S-, -O-, -CH=CH- R1-R7, equal or different can be hydrogen, alkyl C1-C4, alkenyl C2...  
WO/2009/134570A2
Disclosed are tri-nuclear metal complexes and salts thereof, such as tri-nuclear osmium or ruthenium complexes or salts thereof, suitable for use as electrochemical labels. Also disclosed are oligonucleotide probes with an attached elect...  
WO/2009/134570A3
Disclosed are tri-nuclear metal complexes and salts thereof, such as tri-nuclear osmium or ruthenium complexes or salts thereof, suitable for use as electrochemical labels. Also disclosed are oligonucleotide probes with an attached elect...  
WO/2009/133269A1
The invention relates to compounds of the formula (I) in which R1, R2 and R3 are identical or different and each represent a hydrogen atom or a group of the formula (A). The invention can be used for drugs.  
WO/2009/127339A1
The present invention relates to nanoemulsions comprising alkyl and/or alkenyl ethers of alkyl and/or alkenyl(poly)glycosides, a method for the production thereof and use thereof. The present invention further relates to alkyl and/or alk...  
WO/2009/125819A1
Disclosed is a compound useful as an active ingredient for a pharmaceutical composition having an α-amylase-inhibiting activity, particularly a pharmaceutical composition for the treatment of diabetes. Studies have been made for discove...  
WO/2009/126556A1
Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, ...  
WO/2009/126737A3
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin ...  
WO/2009/126737A2
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin ...  
WO/2009/124468A1
Anthracycline antibiotic derivatives with anticancer activity, i.e. the compounds of formula (I). The present anthracycline antibiotic derivatives has the same activity as or higher activity than that of the known medicaments such as dox...  
WO/2009/121939A2
This invention relates to a compound of generic formula (I): (I) as well as a pharmaceutically acceptable salt thereof, a tautomer, optical isomer or a mixture of optical isomers in any proportion, in particular a mixture of enantiomers,...  
WO/2009/121939A3
This invention relates to a compound of generic formula (I): (I) as well as a pharmaceutically acceptable salt thereof, a tautomer, optical isomer or a mixture of optical isomers in any proportion, in particular a mixture of enantiomers,...  
WO/2009/119692A1
Disclosed are: a novel glycolipid effective for the treatment of caner or the like; a novel intermediate for the synthesis of the novel glycolipid; a pharmaceutical agent comprising the novel glycolipid; and others. Specifically disclose...  
WO/2009/117196A8
Methods for utilizing the anticancer properties of terpenoid saponin compounds so as to modulate adhesion proteins, inhibit angiogenesis in tumors, modulate gene expression, modulate angiopoietin, enhance an immune response, provide adju...  
WO/2009/117196A1
Methods for utilizing the anticancer properties of terpenoid saponin compounds so as to modulate adhesion proteins, inhibit angiogenesis in tumors, modulate gene expression, modulate angiopoietin, enhance an immune response, provide adju...  
WO/2009/112951A3
Method for preparing the disaccharide [α-D-Gldp(1→3)]-α-L-Rhap-YR wherein Y is selected from -O- and -S- and R is selected from the group consisting of: C1-C6 alkyl, C1-C6 alkenyl, aryl, allyl, -CO-alkyl (C1-C6), -CO-alkenyl (C1-C6),...  
WO/2009/112950A3
Method for preparing the disaccharide α-D-glucopyranosyl-(1→4)- 2-N-acetyl-2-deoxy-α-D-glucopyranoside, comprising the step of using a mutant of a wild type glycoside hydrolase.  
WO/2009/107853A3
An agent for preventing or ameliorating skin aging, which exhibits a more excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin. An agent for preventing or ameliorating skin aging,...  
WO/2009/107853A2
An agent for preventing or ameliorating skin aging, which exhibits a more excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin. An agent for preventing or ameliorating skin aging,...  
WO/2009/108680A3
Exemplary embodiments of this invention encompass a method for degrading rebaudioside A and the rebaudioside A derivative products derived therefrom. In particular, this invention relates to a method for degrading rebaudioside A composit...  
WO/2009/108680A2
Exemplary embodiments of this invention encompass a method for degrading rebaudioside A and the rebaudioside A derivative products derived therefrom. In particular, this invention relates to a method for degrading rebaudioside A composit...  
WO/2009/101213A1
The present invention relates to an enzyme called chitinosanase which is obtained from the fungus Alternaria alternate, said enzyme breaking down chitosane and specifically cleaving the glycosidic GIcNAc-GIcN bond in chitosane, DNA seque...  
WO/2009/102928A3
The invention provides compounds and methods for making adenosine-ribofuranoside tetraphosphate compounds. The compounds are contemplated to have activity at the P2Y receptor and may be used in the treatment of medical disorders such as ...  
WO/2009/102736A1
The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.  
WO/2009/098400A1
The invention relates to a chemical compound of the disaccharide type of the following general formula (A): where, Z = O or S; X1 = azido or NHCOR3 where R3 = 1 -5 c alkyl or aryl, X2 = benzyl, H or sulfonate, X3 = -CH2φ, -CHφ forming ...  
WO/2009/095588A2
The invention relates to compounds of the formula (I) in which: R1 = OH or NH2; OR2, OR3, OR4 and OR5 form alcohol, ether, ester, carbonate, carbamate, sulphonate or sulphamate functions; and if R5 = H, if R2 =R3=R4, then R2, R3 and R4 ...  
WO/2009/095588A3
The invention relates to compounds of the formula (I) in which: R1 = OH or NH2; OR2, OR3, OR4 and OR5 form alcohol, ether, ester, carbonate, carbamate, sulphonate or sulphamate functions; and if R5 = H, if R2 =R3=R4, then R2, R3 and R4 ...  
WO/2009/097596A1
The present disclosure provides compositions and methods for the treatment and elimination of chronic intracellular infections in cells or organisms. The compositions may include one or more acidic substances and one or more antimicrobia...  
WO/2009/096503A1
Disclosed is a compound having a novel structure, few adverse side effects and an excellent inhibitory activity on human SGLT1 and/or SGLT2, or a hydrate of the compound. Also disclosed is a pharmaceutical composition for treating and/or...  
WO/2009/093604A1
This object aims to provide an organic nanotube manufacturing method and an organic nanotube manufacturing device that pressurize an organic nanotube material dispersion solution comprised of an organic nanotube material and an organic s...  
WO/2009/086720A1
2,3,4,6-tetra-O-acetyl-D-glucopyranosyl-[N,N'-di-(2-chloroet hyl)]-phosphoric acid diamide I, its α-configuration II and its β-configuration III. These compounds show inhibitory action on transplantation tumors in mouse from the pharma...  

Matches 401 - 450 out of 11,277